Abstract Jiangsu Chia-Tai Tianqing Pharmaceutical and Advenchen Laboratories are co-
developing anlotinib (Focus V®) for the treatment of advanced cancer. Anlotinib is an oral …

Lung cancer remains the leading cause of cancer-related deaths despite recent
breakthroughs in immunotherapy. The widely embraced cancer stem cell (CSC) theory has …

Abrogating tumor angiogenesis by inhibiting vascular endothelial growth factor receptor‐2
(VEGFR 2) has been established as a therapeutic strategy for treating cancer. However …

Background Anlotinib has been demonstrated in clinical trials to be effective in prolonging
the progression-free survival (PFS) and overall survival (OS) of refractory advanced …

Tumor growth inhibition can be achieved by inhibiting angiogenesis, which has been a field
of great concern in recent years. Important targets to inhibit angiogenesis include vascular …

Background Anlotinib has been demonstrated its anti-tumor efficacy on non-small cell lung
cancer (NSCLC) in clinical trials at 3rd line. However, anlotinib resistance occurs during its …

To the Editor Cowan et al1 explored the global burden of multiple myeloma (MM) from 1990
to 2016 and reported on the incidence, treatment choices, and frequency of stem cell …

Background Although many studies have defined mechanisms of resistance to EGFR‐TKIs,
acquired resistance remains the major limitation of monotherapy with EGFR‐TKIs. Methods …

The oral multi-targeted tyrosine kinase inhibitor (TKI) anlotinib is effective for non-small cell
lung cancer (NSCLC) in clinical trials at 3rd line. However, a fraction of patients remains non …

Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
represent the standard of care for patients with metastatic non-small-cell lung cancer …